A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) at 15 to 90 mg Every 12 Hours for Relief of Moderate to Severe Pain in Patients With Osteoarthritis or Low Back Pain Who Require Opioid Treatment for an Extended Period of Time.

Trial Profile

A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) at 15 to 90 mg Every 12 Hours for Relief of Moderate to Severe Pain in Patients With Osteoarthritis or Low Back Pain Who Require Opioid Treatment for an Extended Period of Time.

Completed
Phase of Trial: Phase III

Latest Information Update: 19 May 2012

At a glance

  • Drugs Hydrocodone (Primary)
  • Indications Musculoskeletal pain
  • Focus Therapeutic Use
  • Sponsors Cephalon
  • Most Recent Events

    • 30 Dec 2011 Actual patient number (391) and trial location (USA) added as reported by ClinicalTrials.gov.
    • 30 Dec 2011 Actual end date (August 2011) added as reported by ClinicalTrials.gov.
    • 30 Dec 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top